Recombinant CLDN18.2 (Zolbetuximab Biosimilar) antibody

Catalog No. ABIN7795131

The Humanized Monoclonal anti-CLDN18.2 (Zolbetuximab Biosimilar) antibody has been validated for FACS and in vivo. It is suitable to detect CLDN18.2 (Zolbetuximab Biosimilar) in samples from Human.

Quick Overview for Recombinant CLDN18.2 (Zolbetuximab Biosimilar) antibody (ABIN7795131)

Target: CLDN18.2 (Zolbetuximab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This CLDN18.2 (Zolbetuximab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-CLDN18.2 (Zolbetuximab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Zolbetuximab Biosimilar, Claudin 18.2 Monoclonal Antibody

Characteristics: What is zolbetuximab biosimilar research grade? Zolbetuximab is a humanized monoclonal antibody directed against the human protein Claudin 18.2 (the isoform 2 of Claudin), and potentially used for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. Zolbetuximab is an Fc-engineered, humanized, monoclonal antibody (IgG1κ isotype). Zolbetuximab biosimilar uses the same protein sequences as the potential therapeutic antibody zolbetuximab . Claudin-18 in humans is a protein encoded by the CLDN18 gene. The CLDN18 protein belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. Isoform 2 (Claudin 18.2) is abundant in gastric tumors.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human Claudin 18.2

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for CLDN18.2 (Zolbetuximab Biosimilar)

Target: CLDN18.2 (Zolbetuximab Biosimilar)

Alternative Name: Zolbetuximab Biosimilar

Target Type: Biosimilar